Core Viewpoint - Jiukang Bio has received a medical device registration certificate for its Digoxin assay kit, which is valid until October 16, 2030, indicating a significant regulatory milestone for the company [1] Company Summary - Jiukang Bio (300406) announced the receipt of a medical device registration certificate from the Beijing Drug Administration for its Digoxin assay kit [1] - The assay kit is designed for the quantitative measurement of Digoxin levels in human serum or plasma [1] Industry Summary - The approval of the Digoxin assay kit reflects ongoing developments in the medical device sector, particularly in diagnostic tools [1]

Group 1 - Sanwang Communication plans to repurchase shares worth 20-40 million yuan for employee stock incentive plans [1] - Ankrui reported a net profit of 192 million yuan for the first three quarters, a year-on-year increase of 21.31% [1] - Taishan Petroleum's net profit for the first three quarters reached 113 million yuan, up 112.32% year-on-year [1] - Zhejiang Xiantong achieved a net profit of 152 million yuan for the first three quarters, a 17.4% increase year-on-year [1] Group 2 - Xuanji Information reported a net loss of 173 million yuan for the first three quarters [1] - Mailande's net profit slightly decreased by 0.07% to 96 million yuan for the first three quarters [1] - Tengjing Technology's subsidiary received a sales order worth 87.61 million yuan [1] Group 3 - Hotgen Biotech's affiliate achieved positive results in Phase Ib clinical trials for the innovative drug SGC001 [1] - Zhongyan Dadi won a bid for a sports project in Beijing worth 74.04 million yuan [1] - Henghui Security's net profit decreased by 12.85% to 81.98 million yuan for the first three quarters [1] Group 4 - Xiongdi Technology's net profit increased by 71.16% to 18.38 million yuan for the first three quarters [1] - Meilixin reported a net loss of 215 million yuan for the first three quarters [1] - Haichen Pharmaceutical's net profit grew by 16.22% to 32.68 million yuan for the first three quarters [1] Group 5 - Qiaoyuan Co. reported a net profit of 181 million yuan for the first three quarters, a 40.54% increase year-on-year [1] - Fuda Co. achieved a net profit of 221 million yuan for the first three quarters, up 83.27% year-on-year [1] - Xianggang Technology's net profit surged by 186.19% to 95.47 million yuan for the first three quarters [1] Group 6 - ST Nanchuan received a restriction order from the court due to a financial dispute [1] - Changyou Technology announced the dismissal of two vice presidents [1] - Haoyuan Automotive received a project confirmation for an automatic parking system worth 576 million yuan [1] Group 7 - Jiuzhou Biotech obtained a medical device registration certificate for a diagnostic kit [1] - Shihua Machinery signed an investment intention letter for a subsidiary's capital increase [1] - Zhuhai Mian Group plans to transfer 100% equity of Gree Real Estate [1] Group 8 - Dalian Heavy Industry reported a net profit of 490 million yuan for the first three quarters, a 23.97% increase year-on-year [1] - Haimeng Data reported a net loss of 75.43 million yuan for the first three quarters [1] - Feilong Co. achieved a net profit of 287 million yuan for the first three quarters, a 7.54% increase year-on-year [1] Group 9 - Kaipu Testing reported a net profit of 57.84 million yuan for the first three quarters, a 3.34% increase year-on-year [1] - Ganyue Express signed a strategic cooperation agreement with a major energy company [1] - Tuoshan Heavy Industry's controlling shareholder plans to reduce its stake by 2.82% [1] Group 10 - Yiatong's shareholder plans to reduce its stake by 1% [1] - Weishi Electronics reported a net profit of 24.29 million yuan for the first three quarters, a 22.59% decrease year-on-year [1] - Shensi Electronics won a bid for a data space construction project worth 161 million yuan [1] Group 11 - Xiechuang Data plans to purchase server assets worth up to 4 billion yuan [1] - Shandong Express's controlling shareholder plans to transfer 7% of its shares [1] - ST Huapeng's subsidiary received a government subsidy of 4.65 million yuan [1] Group 12 - Jieqiang Equipment's shareholder plans to reduce its stake by 1% [1] - China Jushi reported a net profit of 2.568 billion yuan for the first three quarters, a 67.51% increase year-on-year [1] - ST Fanli reported a net loss of 44.78 million yuan for the first three quarters [1] Group 13 - Xiyu Tourism reported a net profit of 98.58 million yuan for the first three quarters, a 14.51% decrease year-on-year [1] - Abison reported a net profit of 185 million yuan for the first three quarters, a 57.33% increase year-on-year [1] - Huayan Precision reported a net profit of 70.76 million yuan for the first three quarters, a 31.07% increase year-on-year [1] Group 14 - Jiangling Motors reported a net profit of 74.9 million yuan for the first three quarters, a 35.76% decrease year-on-year [1]

Core Viewpoint - Company has received a medical device registration certificate for its Digoxin assay kit, which is expected to enhance its product line in the in vitro diagnostic sector and improve its market competitiveness [1] Group 1 - The product name is Digoxin Assay Kit (Magnetic Particle Chemiluminescent Immunoassay) [1] - The kit is designed for the quantitative measurement of Digoxin levels in human serum or plasma [1] - The registration certificate number is 京械注准20252400878 [1] Group 2 - The acquisition of the medical device registration certificate enriches the company's product offerings in the field of in vitro diagnostics [1] - This development is anticipated to positively impact the company's core competitiveness and market expansion capabilities [1] - The company expects this to have a favorable effect on its future operations [1]

Core Viewpoint - Jiukang Bio (300406) has received a medical device registration certificate for its digoxin assay kit from the Beijing Drug Administration, indicating a significant regulatory approval for the company’s product in the healthcare market [1] Company Summary - The digoxin assay kit is designed for the quantitative measurement of digoxin levels in human serum or plasma, which highlights the company's focus on developing diagnostic tools for critical health monitoring [1] Industry Summary - The approval of the digoxin assay kit reflects the growing demand for reliable diagnostic solutions in the healthcare industry, particularly in the area of cardiac health management [1]

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-092 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 地高辛测定试剂盒 （磁微粒化学发光 | 京 械 注 准 20252400878 | Ⅱ | 自批准之日起有效期 至 2030 年 10 月 16 日 | 本试剂盒用于体外定量 测定人血清或血浆中地 | | | 免疫分析法） | | | | 高辛（DIG）的含量。 | 关于取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： 上述产品医疗器械注册证的取得，丰富了公司在体外诊断化学发光细分 领域产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能 ...

Group 1 - The core viewpoint of the news is that Jiukang Bio's stock performance and financing activities indicate a mixed outlook, with a slight increase in stock price but a significant net financing outflow on October 20 [1] - On October 20, Jiukang Bio's stock rose by 0.53%, with a trading volume of 31.75 million yuan. The net financing buy was -4.14 million yuan, indicating more financing repayment than new purchases [1] - As of October 20, Jiukang Bio's total financing and securities lending balance was 182 million yuan, with a financing balance of 181 million yuan, accounting for 2.34% of the circulating market value, which is below the 50th percentile level over the past year [1] Group 2 - As of June 30, Jiukang Bio had 18,500 shareholders, an increase of 21.57% from the previous period, while the average circulating shares per person decreased by 17.73% to 22,920 shares [2] - For the first half of 2025, Jiukang Bio reported operating revenue of 668 million yuan, a year-on-year decrease of 18.67%, and a net profit attributable to shareholders of 175 million yuan, down 30.01% year-on-year [2] - Since its A-share listing, Jiukang Bio has distributed a total of 1.214 billion yuan in dividends, with 585 million yuan distributed in the last three years [3]

Group 1 - Yonghe Co., Ltd. reported a net profit of 469 million yuan for the first three quarters, a year-on-year increase of 220.39% [1] - Jinli Permanent Magnet achieved a net profit of 515 million yuan, reflecting a year-on-year growth of 161.81% [1][2] - Sanhe Pharmaceutical Auxiliary's net profit increased by 8.28% year-on-year, reaching 133 million yuan [2] Group 2 - Jiahuan Technology experienced a net profit decline of 26.53%, totaling 55.35 million yuan [3] - Wuchan Huaneng reported a net profit decrease of 15.10%, amounting to 453 million yuan [3] - Chuan Investment Energy's net profit fell by 4.54%, totaling 4.22 billion yuan [4][5] Group 3 - Dayang Bio's net profit grew by 56.12%, reaching 80 million yuan [5] - Weili Medical reported a net profit increase of 14.94%, totaling 192 million yuan [6] - People's Tongtai's net profit decreased by 45.69%, amounting to 112 million yuan [7] Group 4 - Jiuhuan Bio received a medical device registration certificate for its NT-proBNP test kit [8] - Jincheng Pharmaceutical's subsidiary obtained a drug registration certificate for a specific injection [9] - Guangdian Yuntong's subsidiary acquired a money service operator license in Hong Kong [10] Group 5 - Dash Intelligent won a bid for a project worth 96 million yuan related to the Shijiazhuang subway [10] - Alloy Investment's net profit increased by 124.87%, reaching 7.26 million yuan [11] - Kaile Co., Ltd. reported a net profit growth of 159.14%, totaling 21.63 million yuan [12] Group 6 - Chuanjinno's net profit surged by 175.61%, reaching 304 million yuan [14] - Rijiu Optoelectronics reported a net profit increase of 36.54%, totaling 76.91 million yuan [15] - Dazhu CNC's net profit grew by 142.19%, amounting to 492 million yuan [15] Group 7 - Nairui Radar expects a net profit increase of 181% for the first three quarters [17] - Suzhou Tianmai successfully acquired land use rights for a new manufacturing project [19] - Aokai Pharmaceutical announced clinical research data for its innovative drug at a major conference [21][22] Group 8 - Jilin Aodong's subsidiary passed the consistency evaluation for a specific injection [24] - Qinxin Environment announced the resignation of a board member [25] - *ST Baoying is planning a change in control, leading to a stock suspension [26] Group 9 - Jianlang Hardware's director plans to reduce holdings by up to 500,000 shares [27] - Taihe Technology's director intends to reduce holdings by up to 606,000 shares [29] - Zhongyuan Securities announced a cash dividend of 0.008 yuan per share [31] Group 10 - Beijing-Shanghai High-Speed Railway plans to distribute a cash dividend of 0.0385 yuan per share [32] - Zhuhai Guanyu expects a net profit increase of 36.88%-55.54% for the first three quarters [34] - Shenglong Co., Ltd. reported a net loss of 72.95 million yuan for the first three quarters [36] Group 11 - Shuangyuan Technology plans to distribute a cash dividend of 0.125 yuan per share [38] - Shaanxi Guotou A reported a net profit increase of 6.6%, totaling 996 million yuan [40] - Sunshine Nuohua intends to invest 15 million yuan in a biotech company [41] Group 12 - Yangjie Technology's net profit increased by 45.51%, reaching 974 million yuan [42] - Xingwang Yuda reported a net profit growth of 260%, totaling 38.37 million yuan [43] - Tongyou Technology turned a profit with a net profit of 9.29 million yuan [44]

Core Viewpoint - The company, Jiukang Biological, has received a medical device registration certificate from the Beijing Drug Administration for its product, the N-terminal pro-brain natriuretic peptide precursor assay kit, utilizing magnetic microparticle chemiluminescent immunoassay technology [1] Group 1 - The product is officially recognized as a medical device, indicating regulatory approval and potential market entry [1] - The assay kit is designed for measuring N-terminal pro-brain natriuretic peptide, which is significant in diagnosing heart-related conditions [1]

Core Viewpoint - The company, Jiukang Biotechnology, has received a medical device registration certificate from the Beijing Drug Administration for its product, the N-terminal pro-brain natriuretic peptide precursor assay kit, which utilizes magnetic particle chemiluminescent immunoassay technology [1] Group 1 - The product is officially recognized as a medical device, indicating regulatory approval and potential market entry [1] - The assay kit is designed for measuring N-terminal pro-brain natriuretic peptide, which is significant in diagnosing heart-related conditions [1]

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-091 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司 关于取得医疗器械注册证书的公告 特此公告。 北京九强生物技术股份有限公司 董事会 2025年10月20日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | N 末端脑利钠肽前 体测定试剂盒（磁微 粒化学发光免疫分 | 京 械 注 准 20252400875 | Ⅱ | 自批准之日起有效期 至 2030 年 10 月 14 日 | 本试剂盒用于体外定量 测定人血清或血浆中 N 末 端 脑 利 钠 肽 前 体 | | | 析法） | | | | （NT-proBNP）的含量。 ...